Semaglutide, a human glucagon-like peptide-1 receptor agonist (GLP-1RA) available in weekly subcutaneous (s.c.) and daily oral formulations, was investigated in the Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN) and Peptide Innovation for Early Diabetes Treatment (PIONEER) phase 3 clinical trial programs, against placebo and active comparators [9,10,11,12,13]
People with complex medical histories, those taking multiple medications with potential interactions, and those with conditions that may be contraindications to semaglutide use should be especially careful about ensuring their submitted health information is comprehensive and accurate
But the reality is the majority of patients will be able to find a dose that is not causing significant side effects. To mitigate side effects, doctors recommend starting patients on a lower dose of the medication and incrementally raising it over a few weeks, she said
Semi-quantitative analysis of protein expression was conducted using ImageJ software, with GAPDH as a loading control